Scandion Oncology A/S presents at the MVA Oncology Network Pitch event at Medicon Village, Lund, Sweden, September 5th, 2018

CSO Jan Stenvang will pitch the background and status of Scandion Oncology A/S. Emphasis will be on the main drug SCO-101, which is ready for Phase II studies, and that Scandion Oncology plans an IPO in the fall of 2018.

The MVA Oncology Network meeting is an investor pitch evening bringing together life science investors and actors within oncology. See the program here: http://mva.org/event/mva-oncology-network-meeting-6/

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union